Form 144 Axsome Therapeutics For: 26 February

Related Posts

ALX Oncology Describes Pivotal Trial Preparation by Late 2026 with Expanded ASPEN-09 Study and $150M Funding

ALX Oncology Describes Pivotal Trial Preparation by Late 2026 with Expanded ASPEN-09 Study and $150M Funding Source link

CoreWeave CEO Michael Intrator sold $8.2 million in shares

CoreWeave CEO Michael Intrator sold $8.2 million in shares Source link

Leave a Reply

Your email address will not be published. Required fields are marked *